01:47 , May 28, 2015 |  BC Extra  |  Company News

Astellas adds muscle disease, ophthalmology TAs

Astellas Pharma Inc. (Tokyo:4503) released a new three-year strategic plan that adds muscle diseases and ophthalmology as therapeutic areas. The company's innovative medicines strategy for FY15-17 also will include development of next-generation vaccines and cell...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

Betmiga mirabegron regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that Betmiga mirabegron from Astellas provides no additional benefit over appropriate comparators defined by Germany's Federal Joint Committee (G-BA) to...
07:00 , Jul 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Adrenergic receptor b3 (ADRB3) Studies in patient samples and mice suggest protecting nestin-positive bone marrow mesenchymal stem cells (MSCs) or their neural regulation could...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Betmiga mirabegron regulatory update

The U.K.'s NICE issued final guidance recommending Betmiga mirabegron from Astellas for the symptomatic treatment of overactive bladder (OAB) only in patients for whom antimuscarinic drugs are not suitable. The guidance is in line with...
07:00 , May 20, 2013 |  BC Week In Review  |  Clinical News

Betmiga mirabegron regulatory update

The U.K.'s NICE issued final appraisal determination (FAD) recommending Betmiga mirabegron from Astellas for the symptomatic treatment of overactive bladder (OAB) only in patients for whom antimuscarinic drugs are not suitable. The committee concluded that...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Astellas sales and marketing update

Astellas' Astellas Pharma Canada Inc. subsidiary launched Myrbetriq mirabegron in Canada to treat overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency. The wholesale acquisition cost is C$1.74 ($1.71) per pill. The...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Clinical News

Myrbetriq mirabegron regulatory update

Astellas' Astellas Pharma Canada Inc. subsidiary said Health Canada approved Myrbetriq mirabegron to treat overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency. The subsidiary said it plans to launch the product...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Clinical News

Betmiga mirabegron regulatory update

The U.K.'s NICE issued draft guidance recommending Betmiga mirabegron from Astellas for the symptomatic treatment of overactive bladder (OAB) only in patients for whom antimuscarinic drugs are contraindicated or clinically ineffective or have unacceptable side...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Astellas sales and marketing update

Astellas' Astellas Pharma Europe Ltd. launched Betmiga mirabegron in the U.K. to treat overactive bladder (OAB). The price of the adrenergic receptor beta 3 (ADRB3) agonist is £29 ($43.92) for a pack of 30 tablets....